Andrew Hall

Andrew Hall

Study Director, Bioanalytical and Analytical Chemistry, Toxikon Corporation

Dr. Andrew Hall received his Ph.D. in natural products chemistry where he studied the isolation, structural elucidation, quantification and pharmacological evaluation of small molecules from marine invertebrate. With a background in analytical FDA regulated data, he has leveraged his expertise to assist in the development of a new capability at Toxikon Corporation, specifically “Kanabolitix” which is located within the Bedford Mass campus of Toxikon Corporation.